✨ Free AI Report
Sarepta Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Sarepta Therapeutics, Inc.
Company Research

Sarepta Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovery and development of RNA-targeted therapeutics, gene therapies, and genetic therapeutic modalities for rare diseases. The company...

Analyst-debate audio for Sarepta Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Sarepta Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

FY2025 revenue grew 16% YoY to $2.2B with net product revenue of $1.86B, positioning Sarepta for profitable growth in precision...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Precision Genetic Medicine & Gene Therapy
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Sarepta Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Sarepta Therapeutics, Inc. Overview

Pro stress-test →

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovery and development of RNA-targeted therapeutics, gene therapies, and genetic therapeutic modalities for rare diseases. The company engineers precision genetic medicine to reclaim futures impacted by rare diseases, building the world's largest gene therapy manufacturing capacity. Core products include EXONDYS 51, VYONDYS 53, AMONDYS 45 for Duchenne muscular dystrophy exon-skipping, and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.

Strategic Profile

Pro stress-test →

The company is positioned to become cash flow positive and profitable on a non-GAAP basis in 2026 with a robust cash position of $954 million in cash and investments as of Q4 2025. ELEVIDYS is the first gene therapy launched in Japan for Duchenne muscular dystrophy, representing significant market expansion. PMO exon-skipping therapies continue demonstrating durable clinical value with exceptional safety and extraordinary real-world outcomes supported by physicians and families.

Competitive Landscape

Pro stress-test →

Sarepta's strategic focus on RNA-targeted technology platforms positions it uniquely in addressing serious diseases. Primary competitors in rare genetic diseases include BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Solid Biosciences, and Ionis Pharmaceuticals (RNAi focused). Sarepta maintains differentiation through commercial gene therapy and exon-skipping platforms with established patient bases.

Industry Context

Sarepta Therapeutics, Inc. operates in Biopharmaceutical - Precision Genetic Medicine & Gene Therapy.

Key facts

Headquarters: Cambridge, MA, US · Revenue: $2.20B (FY2025) · Market cap: $1.99B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Sarepta Therapeutics, Inc..

  • ELEVIDYS demonstrated durable 3-year efficacy in ambulatory Duchenne patients with sustained motor benefit and ~70% slowing of decline on timed tests versus external control.
  • ELEVIDYS faced a challenging 2025 with label restrictions but is pursuing a potential pathway back to serving non-ambulatory patients.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Senior management fireside chat at TD Cowen 46th Annual Health Care Conference
  • February 2026ELEVIDYS commercial launch in Japan by Chugai Pharmaceutical after NHI reimbursement
  • +2 moreTrack every material event for Sarepta Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Sarepta Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gene Therapy PlatformAAV gene therapies for rare genetic disorders→Ultragenyx PlatformRare genetic disease gene therapy and enzyme replacement→RNAi TherapeuticsAntisense oligonucleotide technology for rare diseases→Solid Gene TherapyDMD gene therapy programs→

Compare Sarepta Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Sarepta Therapeutics, Inc. operates in Biopharmaceutical - Precision Genetic Medicine & Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Precision Genetic Medicine & Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Sarepta Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Sarepta Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Sarepta Therapeutics, Inc. do this quarter?”
“Is Sarepta Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Sarepta Therapeutics, Inc. do?+
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovery and development of RNA-targeted therapeutics, gene therapies, and genetic therapeutic modalities for rare diseases. The company...
What is Sarepta Therapeutics, Inc.'s Cyborg Score?+
Sarepta Therapeutics, Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Sarepta Therapeutics, Inc.'s main competitors?+
Named competitors include Gene Therapy Platform, Ultragenyx Platform, RNAi Therapeutics, Solid Gene Therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Sarepta Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Sarepta Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Sarepta Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.